IMCR Immunocore Holdings plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IMCR

Price (delayed)

$28.695

Market cap

$1.46B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.54

Enterprise value

$1.44B

?
Relative Growth: Rel. Growth: 69
Relative Strength: Rel. Strength: 20
Relative Valuation: Rel. Valuation: 15
Relative Profitability: Rel. Profitability: 39

immunocore is a privately owned biotechnology company developing innovative biological therapeutics for the treatment of a range of serious diseases. its world-leading t cell receptor technology exploits the power of ...

Highlights
The revenue is up by 24% year-on-year and by 3.2% since the previous quarter
The gross profit has increased by 24% year-on-year and by 3.3% since the previous quarter
IMCR's net income is down by 27% YoY but it is up by 22% QoQ
The EPS has declined by 26% year-on-year but it has grown by 24% since the previous quarter
Immunocore Holdings's quick ratio has decreased by 36% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://immunocore.com
Peers: OPK ORGO

Key stats

What are the main financial stats of IMCR

IMCR stock price

How has the Immunocore Holdings stock price performed over time
Intraday
0.16%
1 week
-0.95%
1 month
0.61%
1 year
-23.89%
YTD
-17.33%
QTD
-4.83%

Financial performance

How have Immunocore Holdings's revenue and profit performed over time
Revenue
$412.81M
Gross profit
$408.12M
Operating income
-$34.46M
Net income
-$27.57M
Gross margin
98.9%
Net margin
-6.7%
The operating margin rose by 42% YoY and by 27% QoQ
IMCR's operating income is up by 28% year-on-year and by 24% since the previous quarter
IMCR's net income is down by 27% YoY but it is up by 22% QoQ
The net margin has grown by 25% from the previous quarter but it has contracted by 3.1% YoY

Price vs fundamentals

How does IMCR's price correlate with its fundamentals

Growth

What is Immunocore Holdings's growth rate over time

Valuation

What is Immunocore Holdings stock price valuation
P/E
N/A
P/B
3.7
P/S
3.53
EV/EBIT
5,152.13
EV/EBITDA
237.7
EV/Sales
3.49
The EPS has declined by 26% year-on-year but it has grown by 24% since the previous quarter
IMCR's price to book (P/B) is 40% less than its 5-year quarterly average of 6.1 and 14% less than its last 4 quarters average of 4.3
The equity rose by 4% year-on-year and by 3.3% since the previous quarter
The stock's price to sales (P/S) is 77% less than its 5-year quarterly average of 15.3 and 18% less than its last 4 quarters average of 4.3
The revenue is up by 24% year-on-year and by 3.2% since the previous quarter

Efficiency

How efficient is Immunocore Holdings business performance
The return on sales has surged by 108% year-on-year and by 106% since the previous quarter
The ROIC has soared by 100% QoQ and by 100% YoY
The return on assets has increased by 24% since the previous quarter but it has declined by 19% year-on-year
The ROE is up by 23% since the previous quarter but it is down by 20% year-on-year

Dividends

What is IMCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMCR.

Financial health

How did Immunocore Holdings financials performed over time
The total assets is 58% greater than the total liabilities
Immunocore Holdings's quick ratio has decreased by 36% YoY
The current ratio fell by 34% YoY but it rose by 3.5% QoQ
The debt is 11% more than the equity
The equity rose by 4% year-on-year and by 3.3% since the previous quarter
The debt to equity is down by 3.5% since the previous quarter and by 3.5% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.